A British baby’s death this year after getting Novartis’s gene therapy Zolgensma was not caused by a toxic drug reaction, the Swiss drugmaker said, allaying concerns over the $2.1 million-per-patient treatment’s risks.
An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
For two men trained as scientists, the bosses of Britain’s major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit.
With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade.
Steve Figman is the WW VP, Head of Life Sciences for Syntegrity, an RTI International Company. Since 2002 Life Science leaders have leveraged their science-based approach to solving clients’ most important challenges – product launches, competitive counter-launch, BU strategy, market access, Digital, AI, and many others –where speed, new thinking, and internal alignment are critical, but often missing. www.syntegritygroup.com/pharma.